LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.

Schwarz LJ, Fox EM, Balko JM, Garrett JT, Kuba MG, Estrada MV, González-Angulo AM, Mills GB, Red-Brewer M, Mayer IA, Abramson V, Rizzo M, Kelley MC, Meszoely IM, Arteaga CL
J Clin Invest. 2014 124 (12): 5490-502

PMID: 25401474 · PMCID: PMC4348968 · DOI:10.1172/JCI72573

MeSH Terms (26)

Amino Acid Substitution Aminopyridines Animals Breast Neoplasms Dasatinib Drug Resistance, Neoplasm Drug Synergism Estrogen Receptor Modulators Female Gene Expression Regulation, Enzymologic Gene Expression Regulation, Neoplastic Humans Mice Mice, Nude Morpholines Mutation, Missense Phosphatidylinositol 3-Kinases Phosphoinositide-3 Kinase Inhibitors Phosphorylation Protein Kinase Inhibitors Pyrimidines Receptors, Estrogen src-Family Kinases src Homology Domains Thiazoles Xenograft Model Antitumor Assays

Connections (2)

This publication is referenced by other Labnodes entities:

Links